Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: Results of a 2-year follow-up

European Journal of Contraception and Reproductive Health Care

Volumn 3, Issue 2, 1998, Pages 79-84

  Castelo Branco, C ^a   Martinez De Osaba M J ^a   Pons, F ^a   Vanrell, J A ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Bone mineral density; Cycle control; Cyproterone; Desogestrel; Pituitary ovarian and adrenal axis

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; SEX HORMONE;

ADULT; ARTICLE; BLOOD; BONE DENSITY; DRUG EFFECT; FEMALE; HIRSUTISM; HUMAN; METABOLISM;

ADULT; BONE DENSITY; CONTRACEPTIVES, ORAL, SYNTHETIC; CYPROTERONE ACETATE; DESOGESTREL; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HIRSUTISM; HUMANS; PROGESTERONE CONGENERS;

EID: 0032091001     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189809051408     Document Type: Article

References (24)

1. Hreshchshyn MM, Hopkins A, Zylstra S, et al. Associations of parity, breast-feeding, and birth-control pills with lumbar spine and femoral bone densities. Am J Obstet Gynecol 1988; 159: 318-22
2. Lloyd T, Buchanan IR, Ursino GR, et al. Long-term oral contraceptive use does not affect trabecular bone density. Am J Obstet Gynecol 1989; 160: 402-4
3. Kleerekoper M, Brienza RS, Schultz LR, et al. Oral contraceptive use may protect against low bone mass. Arch Int Med 1991; 151: 1971-6
4. Kritz-Silverstein D, Barret-Connor E. Bone mineral content in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health 1993; 83: 100-2
5. Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception 1986; 34: 333-40
6. Recker RR, Davies KM, Hinders SM, et al. Bone gain in young adult women. J Am Med Assoc 1992; 286: 2403-8
7. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-7
8. Del Río L, Pons F, Huguet M, Setoain FT, Setoain J. Anterioposterior versus lateral bone mineral density of spine assessed by dual X-ray absorptiometry. Eur J Nucl Med 1995; 22: 407-12
9. Castelo-Branco C, Martínez de Osaba MJ, Martínez S, Fortuny A. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Metabolism 1996; 45: 24-7
10. Castelo-Branco C, Casals E, Martinez de Osaba MJ, Sanllehy C, Fortuny A. Plasma lipids, lipoproteins and apolipoproteins in hirsute women. Acta Obstet Gynecol Scand 1996; 75: 261-5
11. Castelo-Branco C, Pons F, Martínez de Osaba MJ, Garrido J, Fortuny A. Menstrual history as a determinant of current bone density in young hirsute women. Metabolism 1996; 45: 515-18
12. Castelo-Branco C, Martinez de Osaba MJ, Vanrell JA, Fortuny A, González-Merlo J. Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function. Maturitas 1993; 17: 101-11
13. Gambacciani M, Spinetti A, Cappagli B, et al. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas 1994: 19: 125-31
14. Gallagher JC, Riggs BL, DeLuca HF. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab 1980; 51: 1359-64
15. Bone HG, Bikle DD, Burkman RT. Oral contraceptive use is associated with increased vitamin D metabolite levels in premenopausal women. Presented at the 14th Annual Meeting of the American Society of Bone Mineral Research, September 1992: abstr
16. 3. J Clin Invest 1981; 67: 589-96
17. Bikle DD, Halloran BP, Harris S, et al. Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels. J Clin Endocrinol Metab 1992; 75: 519-23
18. Cundy T, Reid OR, Roberts H. Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br Med J 1991; 303: 13-18
19. Rittmaster RS. Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 1995; 80: 2259-63
20. Sugimoto AK, Hodsman AB, Nisker JA. Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertil Steril 1993; 60: 672-4
21. Castelo-Branco C, Martínez de Osaba MJ, Pons F, Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism 1997; 46: 437-40
22. Falsetti L, Pasinetti F. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil Steril 1994; 61: 817-22
23. Leather AT, Studd JWW, Watson NR, Holland EFN. The prevention of bone loss in young women treated with GnRH-analogues with 'add-back' estrogen therapy. Obstet Gynecol 1993; 81: 104-7
24. Judd HL. Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy. Am J Obstet Gynecol 1992; 166: 752-6